Card image cap
Moderna to set up mRNA vaccine facility in Kenya

US drugs and vaccines maker Moderna has signed a memorandum of understanding with Kenya’s government for its first mRNA vaccine manufacturing facility in Africa. The company said in a statement that its goal is to produce up to 500 million doses of vaccines a year for the continent – with a focus on drug substance manufacturing, though the facility could be expanded to include fill-and-finish work. Meanwhile, Moderna is also working on plans to allow it to fill doses of its COVID-19 vaccine in Africa as early as 2023, subject to demand. Africa, currently the least-vaccinated region in the world against the coronavirus – relies on imports for about 99 percent of its vaccine needs.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.

Supported by Koye Pharmaceuticals

Submit a Comment